Mitochondrial purine and pyrimidine metabolism and beyond.
Liya Wang
https://pubmed.ncbi.nlm.nih.gov/27906631/Actively Recruiting
Led by Kenneth Myers, MD · Updated on 2026-10-19
200
Participants Needed
1
Research Sites
26 weeks
Total Duration
Mitochondrial DNA depletion syndromes MDS are a group of inherited disorders that cause severe reduction in mitochondrial DNA, leading to problems with energy production in various tissues. These disorders are caused by mutations in certain nuclear genes and present with diverse symptoms affecting muscles, the brain, liver, and digestive system. There is currently no effective treatment for MDS, and care mainly focuses on managing symptoms. Research suggests that increasing specific deoxyribonucleosides might help prevent mitochondrial DNA depletion. This phase II open-label trial studies the safety, tolerability, and effectiveness of a combination of two deoxynucleosides, deoxycytidine and deoxythymidine, given orally daily to children and adults aged 0 to 60 years with confirmed MDS and mutations in specific genes. The dosage increases weekly from 100 mgkg to 400 mgkg over approximately 5 years. The study aims to provide early treatment to restore mitochondrial function and improve clinical outcomes. Participants will undergo regular clinical and neurological evaluations using mitochondrial disease scales, seizure diaries, and quality of life questionnaires. Laboratory tests will monitor blood counts, liver and kidney function, muscle damage markers, mitochondrial DNA levels, and mitochondrial function through various blood and urine tests. Safety is assessed by tracking adverse events, including diarrhea and any serious effects, throughout the treatment period. The total participation duration can extend up to 5 years.
CONDITIONS
Deoxynucleosides Pyrimidines as Treatment for Mitochondrial Depletion Syndrome
K
Kenneth Alexis MD Myers, MD PhD FRCPC
S
Saoussen Dr Berrahmoune, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Kenneth Myers, MD
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 260 weeks
Participants receive daily oral doses of deoxycytidine and deoxythymidine with doses increasing over time according to the study protocol.
Regular visits for clinical and neurological assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Liya Wang
https://pubmed.ncbi.nlm.nih.gov/27906631/M C Lara, B Weiss, I Illa...
https://pubmed.ncbi.nlm.nih.gov/16971699/Omar Hikmat, Charalampos Tzoulis, Wui K Chong...
https://pubmed.ncbi.nlm.nih.gov/30228318/Yolanda Cámara, Emiliano González-Vioque, Mauro Scarpelli...
https://pubmed.ncbi.nlm.nih.gov/23817075/Hasan O Akman, Beatriz Dorado, Luis C López...
https://pubmed.ncbi.nlm.nih.gov/18467430/Salvatore DiMauro, Eric A Schon
https://pubmed.ncbi.nlm.nih.gov/12826641/Anu Suomalainen, Pirjo Isohanni
https://pubmed.ncbi.nlm.nih.gov/20444604/Ayman W El-Hattab, Fernando Scaglia
https://pubmed.ncbi.nlm.nih.gov/23385875/Ayman W El-Hattab, William J Craigen, Fernando Scaglia
https://pubmed.ncbi.nlm.nih.gov/28215579/M J Absalon, C O Harding, D R Fain...
https://pubmed.ncbi.nlm.nih.gov/11182283/Kenneth Myers, MD
Lead Sponsor